EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Present and Future Perspectives in the Treatment of Liver Fibrosis

Lucia Cerrito iD, Linda Galasso, Jacopo Iaccarino iD, Alessandro Pizzi, Fabrizio Termite iD, Giorgio Esposto, Raffaele Borriello, Maria Elena Ainora, Antonio Gasbarrini iD, Maria Assunta Zocco iD

Pharmaceuticals · 03.09.2025 · 18 (9) · 1321

DOI: 10.3390/ph18091321 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 03.09.2025. Verfasst von Lucia Cerrito und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of Rome, 00168…. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 240 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Liver fibrosis is a progressive consequence of chronic liver injury that can evolve into cirrhosis, liver failure, or hepatocellular carcinoma, representing a major global health burden. Fibrogenesis is driven by hepatic stellate cell (HSC) activation, excessive extracellular matrix deposition, and structural disruption of liver tissue, with transforming growth factor-β (TGF-β) signaling and inflammatory mediators as central pathways. Current therapies primarily target the underlying causes, which may halt disease progression but rarely reverse established fibrosis. This review aims to outline current and emerging therapeutic strategies for liver fibrosis, informing both clinical practice and future research directions.

Methods

A narrative synthesis of preclinical and clinical evidence was conducted, focusing on pharmacological interventions, microbiota-directed strategies, and innovative modalities under investigation for antifibrotic activity.

Results

Bile acids, including ursodeoxycholic acid and derivatives, modulate HSC activity and autophagy. Farnesoid X receptor (FXR) agonists, such as obeticholic acid, reduce fibrosis but are limited by adverse effects. Fatty acid synthase inhibitors, exemplified by denifanstat, show promise in metabolic dysfunction-associated steatohepatitis (MASH). Additional strategies include renin–angiotensin system inhibitors, omega-3 fatty acids, and agents targeting the gut–liver axis. Microbiota-directed interventions—probiotics, prebiotics, symbiotics, antibiotics (e.g., rifaximin), and fecal microbiota transplantation—are emerging as potential modulators of barrier integrity, inflammation, and fibrogenesis, though larger clinical trials are required. Reliable non-invasive biomarkers and innovative trial designs, including adaptive platforms, are essential to improve patient selection and efficiently evaluate multiple agents and combinations.

Conclusions

Novel modalities such as immunotherapy, gene editing, and multi-targeted therapies hold additional potential for fibrosis reversal. Continued translational efforts are critical to establish safe, effective, and accessible treatments for patients with liver fibrosis.

Schlagwörter

Stichwörter der Autor:innen

farnesoid X receptor (FXR) agonistsgut–liver axishepatic stellate cells (HSC)liver fibrosistransforming growth factor-β (TGF-β)

Autor:innen und Institutionen

  • Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of Rome, 00168 Rome, Italy.
  • CEMAD Digestive Disease Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of Rome, 00168 Rome, Italy.

ORCID-Profile: Lucia Cerrito, Jacopo Iaccarino, Fabrizio Termite, Antonio Gasbarrini, Maria Assunta Zocco

Zitieren

APA

Cerrito, L., Galasso, L., Iaccarino, J., Pizzi, A., Termite, F., Esposto, G., Borriello, R., Ainora, M. E., Gasbarrini, A., & Zocco, M. A. (2025). Present and Future Perspectives in the Treatment of Liver Fibrosis. Pharmaceuticals, 18(9), 1321. https://doi.org/10.3390/ph18091321

Vancouver

Cerrito L, Galasso L, Iaccarino J, Pizzi A, Termite F, Esposto G, et al. Present and Future Perspectives in the Treatment of Liver Fibrosis. Pharmaceuticals. 2025;18(9):1321. doi:10.3390/ph18091321

BibTeX
@article{Cerrito2025,
  author = {Cerrito, Lucia and Galasso, Linda and Iaccarino, Jacopo and Pizzi, Alessandro and Termite, Fabrizio and Esposto, Giorgio and Borriello, Raffaele and Ainora, Maria Elena and Gasbarrini, Antonio and Zocco, Maria Assunta},
  title = {Present and Future Perspectives in the Treatment of Liver Fibrosis},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {9},
  pages = {1321},
  doi = {10.3390/ph18091321}
}
Kostenlos starten →